Topic: Mechanisms of Resistance in Solid Tumors and Precision Medicine Approaches

The management of solid tumors has been revolutionized by the development of targeted therapies and immunotherapies, yet drug resistance remains a critical barrier to long-term patient survival. Resistance arises through complex and adaptive mechanisms, including clonal evolution, tumor heterogeneity, and dynamic crosstalk within the tumor microenvironment, which enable cancer cells to evade therapeutic pressure, leading to disease progression.

This Special Issue seeks to unravel the molecular and cellular basis of resistance in solid tumors. We invite contributions that explore innovative strategies to counteract resistance, such as combination therapies, biomarker-driven approaches, and interventions targeting the tumor microenvironment. Areas of focus include, but are not limited to, immune evasion mechanisms, epigenetic and metabolic adaptations, and the role of non-coding RNAs in treatment resistance.

Our goal is to showcase cutting-edge research that bridges laboratory discoveries with clinical applications, ultimately advancing personalized cancer treatment. We welcome original research articles, reviews, and perspectives that provide novel insights into overcoming resistance and improving therapeutic outcomes for patients with solid tumors.

Topics of interest include, but are not limited to：
● Mechanisms of intrinsic and acquired resistance to targeted therapies;
● Tumor microenvironment-mediated immunosuppression and immune evasion;
● Epigenetic and metabolic adaptations in treatment-resistant tumors;
● Novel biomarkers for predicting and monitoring therapeutic response;
● Strategies to overcome resistance through drug combinations or nanomedicine;
● Clinical trials focused on resistance reversal and personalized therapy;
● Computational models and applications of artificial intelligence in resistance research.

Drug resistance mechanisms, solid tumors, precision medicine, tumor microenvironment, biomarkers, immunotherapy resistance, targeted therapy, tumor heterogeneity